215 related articles for article (PubMed ID: 20587853)
1. Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study.
Lang JP; Melin P; Ouzan D; Rotily M; Fontanges T; Marcellin P; Chousterman M; Cacoub P;
Antivir Ther; 2010; 15(4):599-606. PubMed ID: 20587853
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
[TBL] [Abstract][Full Text] [Related]
4. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C.
Martín-Santos R; Díez-Quevedo C; Castellví P; Navinés R; Miquel M; Masnou H; Soler A; Ardevol M; García F; Galeras JA; Planas R; Solà R
Aliment Pharmacol Ther; 2008 Feb; 27(3):257-65. PubMed ID: 17988237
[TBL] [Abstract][Full Text] [Related]
5. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.
Neri S; Bertino G; Petralia A; Giancarlo C; Rizzotto A; Calvagno GS; Mauceri B; Abate G; Boemi P; Di Pino A; Ignaccolo L; Vadalà G; Misseri M; Maiorca D; Mastrosimone G; Judica A; Palermo F
J Clin Gastroenterol; 2010 Oct; 44(9):e210-7. PubMed ID: 20838237
[TBL] [Abstract][Full Text] [Related]
6. DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN.
Vabo IL; Ferreira LE; Pace FH
Arq Gastroenterol; 2016; 53(1):20-4. PubMed ID: 27281500
[TBL] [Abstract][Full Text] [Related]
7. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.
Masip M; Tuneu L; Pagès N; Torras X; Gallego A; Guardiola JM; Faus MJ; Mangues MA
Int J Clin Pharm; 2015 Dec; 37(6):1143-51. PubMed ID: 26267215
[TBL] [Abstract][Full Text] [Related]
9. Interferon for hepatitis C patients with psychiatric disorders.
Rifai MA; Bozorg B; Rosenstein DL
Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
[No Abstract] [Full Text] [Related]
10. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
[TBL] [Abstract][Full Text] [Related]
11. Interferon for hepatitis C patients with psychiatric disorders.
Asnis GM; De La Garza R; Rego SA; Henderson MA; Reinus JF
Am J Psychiatry; 2004 Dec; 161(12):2332; author reply 2332-4. PubMed ID: 15569920
[No Abstract] [Full Text] [Related]
12. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
Quinn D; Kuchler E; Deming P; Arora S
Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
[No Abstract] [Full Text] [Related]
13. Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort.
Righi E; Beltrame A; Bassetti M; Lindstrom V; Mazzarello G; Dentone C; Di Biagio A; Ratto S; Viscoli C
Infection; 2008 Aug; 36(4):358-61. PubMed ID: 18642111
[TBL] [Abstract][Full Text] [Related]
14. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.
Roffi L; Colloredo G; Pioltelli P; Bellati G; Pozzpi M; Parravicini P; Bellia V; Del Poggio P; Fornaciari G; Ceriani R; Ramella G; Corradi C; Rossini A; Bruno S;
Antivir Ther; 2008; 13(5):663-73. PubMed ID: 18771050
[TBL] [Abstract][Full Text] [Related]
17. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
[TBL] [Abstract][Full Text] [Related]
18. Incidence of psychiatric side effects during pegylated interferon- alpha retreatment in nonresponder hepatitis C virus-infected patients.
Quarantini LC; Bressan RA; Galvão A; Batista-Neves S; Paraná R; Miranda-Scippa A
Liver Int; 2007 Oct; 27(8):1098-102. PubMed ID: 17845538
[TBL] [Abstract][Full Text] [Related]
19. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
Fuster D; Planas R; Gonzalez J; Force L; Cervantes M; Vilaró J; Roget M; García I; Pedrol E; Tor J; Ballesteros AL; Salas A; Sirera G; Videla S; Clotet B; Tural C
Antivir Ther; 2006; 11(4):473-82. PubMed ID: 16856621
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial.
Diez-Quevedo C; Masnou H; Planas R; Castellví P; Giménez D; Morillas RM; Martín-Santos R; Navinés R; Solà R; Giner P; Ardèvol M; Costa J; Diago M; Pretel J
J Clin Psychiatry; 2011 Apr; 72(4):522-8. PubMed ID: 21034680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
